181629-57-2 Usage
Uses
Used in Organic Synthesis:
4-[[5-Oxo-5-(phenylmethoxy)pentyl][(phenylmethoxy)carbonyl]amino]-1-piperidinecarboxylic Acid 1,1-Dimethylethyl Ester is used as a synthetic intermediate for the development of various organic compounds. Its unique structure allows it to be a valuable building block in the synthesis of pharmaceuticals, agrochemicals, and other specialty chemicals.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 4-[[5-Oxo-5-(phenylmethoxy)pentyl][(phenylmethoxy)carbonyl]amino]-1-piperidinecarboxylic Acid 1,1-Dimethylethyl Ester is used as a key component in the development of new drugs. Its specific functional groups and structural features make it a promising candidate for the creation of novel therapeutic agents with potential applications in treating various diseases and medical conditions.
Used in Chemical Research:
4-[[5-Oxo-5-(phenylmethoxy)pentyl][(phenylmethoxy)carbonyl]amino]-1-piperidinecarboxylic Acid 1,1-Dimethylethyl Ester is also utilized in chemical research as a model compound for studying various reaction mechanisms and exploring new synthetic routes. Its reactivity and structural characteristics provide valuable insights into the behavior of similar compounds and contribute to the advancement of chemical knowledge.
Check Digit Verification of cas no
The CAS Registry Mumber 181629-57-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,8,1,6,2 and 9 respectively; the second part has 2 digits, 5 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 181629-57:
(8*1)+(7*8)+(6*1)+(5*6)+(4*2)+(3*9)+(2*5)+(1*7)=152
152 % 10 = 2
So 181629-57-2 is a valid CAS Registry Number.
InChI:InChI=1/C30H40N2O6/c1-30(2,3)38-28(34)31-20-17-26(18-21-31)32(29(35)37-23-25-14-8-5-9-15-25)19-11-10-16-27(33)36-22-24-12-6-4-7-13-24/h4-9,12-15,26H,10-11,16-23H2,1-3H3
181629-57-2Relevant academic research and scientific papers
Semisynthesis of RPR 121056A, a major metabolite of irinotecan (CPT-11)
Bourzat, Jean-Dominique,Vuilhorgne, Marc,Rivory, Laurent P.,Robert, Jacques,Commercon, Alain
, p. 6327 - 6330 (2007/10/03)
The semisynthesis of RPR 121056A (4), a major metabolite of irinotecan (CPT-11, 2) is reported starting from SN-38 (3) and an appropriate side-chain precursor, and using a 2-step sequence. This semisynthesis is based on the 10-O-acylation of SN-38 with the conveniently protected carbamoylchloride derivative 10 followed by cleavage of the benzylic protecting groups by hydrogenolysis. Preliminary in vitro results show that RPR 121056A displays no cytotoxicity.
